Plan ahead for the 2024/2025 RSV season

Introducing the Beyfortus® (nirsevimab-alip) Reservation Program

Order Beyfortus Packaging Image

Optimize Your Planning for the 2024/2025 RSV Season

What is the Beyfortus Reservation Program?

The Beyfortus Reservation Program provides critical insight on customer demand, and we are committed to prioritizing fulfillment of requests placed through this program.

With AstraZeneca, we are expanding the Beyfortus manufacturing network to allow for a significant increase in supply for the 2024/2025 season and cover the entire US demand. In addition, we are producing Beyfortus well in advance of the RSV season, with the vast majority of doses available by October.

The Beyfortus Reservation Program will help to optimize planning and provide access to reserve Beyfortus ahead of the season.
The Reservation Program unlocks additional benefits, including:
  • [New] 2% discount for direct orders
  • Priority shipping, priority shipping, with reserved doses set aside
  • Ability to determine your preferred monthly shipment schedule throughout the RSV season
  • 90-day payment terms
  • Cancellation is possible up to 14 days prior to scheduled shipments*
Once you have qualified for the program by estimating and submitting your Beyfortus forecast, you will be able to take part in the reservation period and receive program benefits.

Here's how it works

The Reservation Program has benefits, but it’s not your only chance to order

Orders can be placed outside of the Reservation Program during the normal order window from September 2024 through February 2025.

  • Go to and place an order as you usually would beginning in September
  • Normal ordering window terms and conditions:
    - Order Now/Ship Now Only: no ability to schedule future shipments
    - Payment terms are limited to 60 days

Total order availability may be affected by overall demand.

Looking for more information?

Download Brochure

Thanks for planning ahead for the 2024/2025 RSV season!

Order Beyfortus Packaging Image

Optimize Your Planning for the 2024/2025 RSV Season


Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Important safety information


Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

  • Hypersensitivity Reactions Including Anaphylaxis: Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.
  • Use in Individuals with Clinically Significant Bleeding Disorders: As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Please see full Prescribing Information.

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.